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Abstract 
 
Introduction: Cancer is known to be a major cause of morbidity and mortality, making it vital to 
deepen cancer research. Colorectal cancer is one of the most common cancers and represents 
the fourth most common cause of death from cancer worldwide. It is a multifactorial disease 
associated with environmental exposure, DNA mutations, lifestyle, inflammation and recently, 
microbiota. 
Aim: The aim of this review is to discuss the most recent scientific advances in the establishment 
of a causality link between intestinal microbiota and colorectal cancer, as well as explore the 
underlying physiopathological mechanisms and theories. It will also be discussed the clinical 
relevance of the subject. 
Results: Most of the studies corroborate a relationship between the microbiota changes and 
tumorigenesis. However, the existence of a causal relation has not yet been fully clarified. More 
and more evidence suggests a collective and multifactorial role of the microbiome. Nevertheless, 
some microorganisms appear to play a prominent role, such as Fusobacterium nucleatum, 
Escherichia coli and Enteroxigenic Bacteroides fragilis. There has been increasing interest in the 
clinical potentials of this association, namely by microbiome modulation and creation of potential 
screening biomarkers.  
Conclusions: There is solid evidence of the relationship between microbiome and colorectal 
cancer. However, it’s not entirely clear yet the causal nature of this relationship, as well as the 
mechanisms and interactions that characterize it to its fullest extent. The most consistently 
associated microorganism, and therefore with the greatest clinical potential is Fusobacterium 
nucleatum. For now, the clinical application of these findings is not a reality, but the potentialities 
are huge.  
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Resumo 
 
Introdução: O cancro constitui uma das principais causas de morbilidade e mortalidade, sendo 
por isso crucial aprofundar a investigação neste campo. O cancro colo-rectal é um dos cancros 
mais comuns e representa a quarta causa mais comum de morte por cancro em todo o mundo. 
É uma doença multifatorial associada a exposição ambiental, mutações genéticas, estilo de vida, 
processos inflamatórios e recentemente, ao microbioma.  
Objetivos: O objetivo desta revisão será analisar e discutir os mais recentes avanços científicos 
no estabelecimento de uma relação de causalidade entre o microbioma intestinal e o cancro colo-
rectal, bem como explorar os mecanismos fisiopatológicos subjacentes e teorias propostas. Esta 
dissertação procurará também abordar a relevância clínica da questão estudada.  
Desenvolvimento: A maioria dos estudos corrobora uma relação entre alterações da microbiota 
e os processos de tumorigénese, no entanto ainda não está totalmente esclarecida a existência 
de uma relação causal. Cada vez mais a evidência sugere um papel coletivo e multifatorial do 
microbioma, no entanto alguns microrganismos aparentam ter um papel de destaque, tais como 
Fusobacterium nucleatum, Escherichia coli e Enteroxigenic Bacteroides fragilis.  Tem havido um 
interesse crescente na investigação das potencialidades clínicas desta associação, 
nomeadamente a nível de modulação da microbiota e criação de possíveis biomarcadores de 
rastreio.  
Conclusões: Há evidência da relação entre o microbioma e o cancro colo-rectal, mas ainda não 
está inteiramente esclarecida a natureza causal da relação, assim como os mecanismos e 
interações que a caracterizam em toda a sua extensão. O microrganismo mais consistentemente 
associado e com maior potencial de aplicação clínica é o Fusobacterium nucleatum. Para já, a 
possibilidade de aplicação clínica destas descobertas ainda não é uma realidade, no entanto as 
potencialidades desta área são amplas.  
 
Palavras-chave 
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Background 
 
Colorectal cancer – Impact and carcinogenesis 
Colorectal cancer is defined as a carcinoma, most commonly adenocarcinoma, in the colon or 
rectum. (1) It is the third most common cancer diagnosed in both men and women in the United 
States, representing 10% of the global cancer incidence burden. (1, 2) It is the fourth most 
common cause of death from cancer worldwide.  
The incidence and death rates for colorectal cancer increase with age, being that 90% of new 
cases and 93% of deaths occur in people older than 50 years. (3) More than 65% of the new 
cases occur in developed countries. (1) 
In Portugal, colorectal cancer is the third most common cancer in men and the second most 
common in women. According to the most recent data (2014), the mortality rate for colon cancer 
was 25.8% and for rectal cancer was 10.3%. There is an asymmetry regarding incidence and 
mortality, comparing the coastal area with the interior, being that the latter has higher incidence 
and mortality rates. The mortality rate is also lower in the urban centers. (4) 
The exact etiology of colorectal cancer is still unknown, but it has been linked with genetic, 
epigenetic and environmental factors. (5) Most colorectal cancer cases are sporadic (70-80%), 
but it can have a hereditary component (20-30%), due to some susceptibility syndromes, such as 
Human Non-polyposis Colon Cancer and Familiar Adenomatous Polyposis. A small part of CRC 
cases (1 – 2 %) can arise as a consequence of inflammatory bowel diseases. (6) 
Colorectal cancer is a heterogeneous disease in terms of both molecular and morphologic 
carcinogenesis pathways. Three molecular carcinogenesis pathways are generally accepted: the 
chromosomal instability, microsatellite instability and CpG island methylator phenotype or 
epigenetic instability pathway. (7) In terms of morphology, it’s known that most colorectal 
carcinomas develop through an adenoma-carcinoma sequence, whether about 10 – 20 % of 
carcinomas may develop via the serrated pathway, a different sequence of morphological 
changes. (6) 
The chromosomal instability pathway is found in about 85% of sporadic colorectal cancers and 
includes activation of oncogenes like KRAS and the inactivation of tumor suppressor genes such 
as APC and p53. (1, 5) The microsatellite instability pathway occurs in about 15% of sporadic 
colorectal cancers, due to an incompetent DNA mismatch repair system, as a result of mutation, 
deletion or promoter methylation of some MMR genes, such as MLH1, MSH2, MSH6 and PMS2 
that codify for the MMR proteins. (6) The epigenetic instability pathway is characterized by 
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hypermethylation of numerous promoter CpG island loci and consequent inactivation of tumor 
suppressor genes or tumor-related genes. (7) 
The classical adenoma-carcinoma sequence begins with conventional adenomas, including 
tubular or tubulovillous adenomas, in which the accumulation of genetic and epigenetic alterations 
leads to epithelial dysplasia and progressive evolution to carcinoma. (1, 5, 7) This pathway is 
driven by chromosomal instability pathway or microsatellite instability pathway and it usually takes 
10 to 15 years until overt cancer. (2) The serrated pathway begins with hyperplastic polyps, 
sessile or traditional serrated adenomas and has epigenetic instability as its initial driving pathway 
and microsatellite instability pathway in a secondary role. (7) 
Although the triggers leading to this onset of DNA mutations and molecular alterations are not 
fully understood, it is known that colorectal cancer is mainly a “lifestyle disease”. (1) In most cases, 
environmental factors such as dietary composition, lack of physical activity, overweight, cigarette 
smoking and heavy alcohol consumption play a vital role in an individual’s risk of colorectal 
cancer. (8, 9) This environmental impact is supported by many migrants’ studies. Among migrants 
from low-risk to high-risk countries, incidence rates of colorectal cancer tend to increase toward 
those of the host country. (8)  
Over the past decade, there has been increasing experimental evidence linking gut microbiome 
and colorectal cancer, as it will be approached further in this essay. (9) 
Therefore, colorectal cancer is one of the major cancers for which modifiable causes may be 
identified and possibly prevented. A better understanding of the mechanisms involved and 
interactions between the environmental factors is crucial in the quest for CRC prevention and 
screening. 
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Overview of the gut microbiome 
 
Most of the human epithelial surfaces host a variety of microorganisms, mainly bacteria, that 
outnumber the human somatic cells by at least a magnitude of 10. However, the greatest number 
of bacterial cells reside in the digestive tract. The microbiome, defined as the collective microflora 
genetic material, is 150 times larger than the human genome. (10) 
In the gastrointestinal tract, quantitative and qualitative variations are seen in the different sites 
from mouth to rectum, due to host factors (pH, transit time, bile acids, digestive enzymes, and 
mucus), nonhost factors (nutrients, medication, and environmental factors) and bacterial factors 
(adhesion capacity, enzymes, and metabolic capacity). (11) The large intestine contains 70% of 
the human microorganisms, approximately 1014 bacteria.(12) It provides a good environment for 
bacterial growth due to an almost neutral pH, reduction of bile salt concentration and pancreatic 
secretion, associated with a slow transit time. (13) 
Evidence based in classical cultivation techniques established that humans were born with a 
sterile gut. However, 60-80% of the total microbiota cannot be cultivated, and more recent 
evidence using sequencing methods suggests that there is colonization prior to birth, for example 
with detection of microbial DNA in premature infants meconium. (11, 14) Then rapidly after birth 
the exposition expands and there’s a diversification and evolution in the composition, with 
progressive stabilization until approximately the age of 2,5 years, in which we have an adult-like 
microbiota community. This early-life period of highly instable microbiota is therefore more 
sensitive to external influences or aggressions.(15) During adulthood the intestinal microflora 
remains relatively stable, with minor fluctuations. (12, 16) In the elderly, there’s a tendency for a 
decrease in bacterial abundance and diversity, which may prone to disease.(17) 
There is a natural interindividual variation caused by genetic characteristics and also age, diet,  
host immune system, health status and antibiotic use. Therefore, each human being has its own 
unique microbiota. (10, 18, 19) However, there are some bacterial species commonly found in 
human gut microbiota, mainly from the phyla Firmicutes (30%-50%), Bacteroidetes (20%-40%), 
followed by Actinobacteria and Verrucomicrobia. (12, 13) In the colon, more than 90% are from 
phyla Bacteroidetes and Actinobacteria.(12) Since the colon is free of oxygen, most microbial 
populations are strictly anaerobic, such as Bacteroides, Eubacterium, Bifidobacterium, 
Peptostreptococcus, and Ruminococcus. (13) Facultative anaerobes like Lactobacilli, 
Enterococci, Streptococci and Enterobacteriaceae are also present but represent a minority. (12) 
This complex, diverse and dynamic communities of microbiota are known to play a significant role 
in health. The microbiota participates in digestion and extraction of nutrients, protection against 
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infection, in the host immune response, drugs metabolism and is also involved in regulation of 
host metabolism. (19) There is evidence, mainly from animal models, of the microbiota important 
effects on the structural development and function of gut-associated lymphoid tissues, T cells and 
B cells. The gut microorganisms also expand the host’s range of metabolic capabilities. They 
participate in the synthesis of micronutrients such as vitamin K, B12 and folic acid, as well as 
absorption of calcium, magnesium and iron. These bacteria account for a large range of 
carbohydrate active enzymes which allow them to break down indigestible dietary residues, 
releasing short chain fatty acids, known to be important for health and immunity. Microbiota can 
also influence drug metabolism. For example, it was discovered that Eggerthella lenta was 
responsible for inactivating digoxin in a subset of individuals. (19) 
We can also divide the microbiota in mucosa-associated and luminal flora, whether the microbes 
penetrate the mucosal layer or are located in the lumen.(12) The luminal bacteria are less 
abundant than the mucosa-associated bacteria. (20) Furthermore, when comparing microbiome 
from stool and mucosal tissue samples, different populations are found. (21) The colonic mucosal 
communities are adherent to surface-associated polysaccharide matrices and are therefore less 
affected by hydrodynamic shear forces. These communities rooted to the mucosa interact with 
the immune system and appear to be more relevant to diseases such as CRC. (5) 
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Methods 
 
For this review, a literature search was performed using the PubMed database. The search key 
terms were (“microbiome" or “microbiota" or "intestinal flora”) and (“colorectal” or “colon” or “rectal” 
or “rectum”) and (“cancer” or “neoplasm” or “neoplasia”). Only articles published in English and 
during the period of January 2013 to June 2016 were selected.  
The articles of the initial search have been screened for their potential eligibility according to the 
content of the title and/or abstract. In a second fase, the initially selected papers were full text 
reviewed, and a final selection was made. Articles considered off-topic, non-relevant or redundant 
in their results were excluded.  
Whenever necessary and relevant, additional papers/documents were included in order to 
complement the review.  
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Microbiota and Colorectal Cancer 
 
Tumorigenesis and dysbiosis – Is there an association? 
One third of cancers worldwide are associated with identified single microbial infections. (22) 
Concerning CRC, investigation linking the colon commensal microbiota with colon cancer begun 
in 1969. (23) Since then, the interplay between intestinal microbiota and CRC has been a growing 
area of research.  
CRC is still one of the most prevalent and lethal cancers, and the screening methods available 
(colonoscopy and FOBT) are either invasive or lack high sensitivity and specificity. (24) The 
human gut hosts a broad and diverse community of bacteria that plays key roles in the host 
immunity and metabolism, and possibly in disease. With this in mind, major research questions 
started to emerge, and the first investigation step was comparing the microbiota of healthy 
individuals with that of colorectal cancer patients.  
Several studies used next generation sequencing techniques to compare luminal (fecal samples) 
and/or mucosa-associated (mucosal biopsy samples or rectal swabs for mucosa-adherent 
specimens) microbiota of CRC patients and healthy individuals. Many of them consistently found 
CRC associated dysbiosis, and Table 2 (page 28) sums up the main bacteria involved.  
Most colorectal carcinomas develop through an adenoma-carcinoma sequence, so the next step 
was trying to understand if dysbiosis is only observed in the context of malignancy or if it begins 
earlier, by the time adenomas appear. Several studies that include microbiome analysis of 
subjects with adenomas were reviewed and the results are also organized and summed up in 
Table 1.   
The overall bacteria diversity in adenomas is reported in some studies as higher than that of the 
normal individuals (25, 26). Regarding CRC patients, studies found both lower bacterial 
population diversity (27-29) and an increasing diversity. (30, 31) Is has been hypothesized that 
the lower diversity detected in diseased sites is due to a selective enrichment of a reduced number 
of potentially pathogenic microorganisms due to specific characteristics of the tumor 
microenvironment, at the expense of many other species, possibly more sensitive to 
environmental changes. (31) The higher bacterial diversity detected in adenoma patients and in 
some groups of CRC patients, could be due to the intense irrigation of tumors and polyps, 
providing more nutrients. (31) Another factor that might be associated with the divergent results 
in CRC microbiome diversity is the different stage of tumor progression in different studies.  
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As we can conclude from Tables 1 and 2, the most consistent finding is an enrichment of 
Fusobacterium in CRC patients and in patients with adenomas, both in the gut lumen and 
mucosa. There is also an enrichment of genus Porphyromonas, Peptostreptococcus and the 
family Enterococcaceae in CRC patients compared to healthy controls. Regarding the phylum 
Proteobacteria, studies are not completely concordant. Some papers report a Proteobacteria 
enrichment in the lumen and mucosa of adenoma patients, specially a significantly increase in 
some genus such as Pseudomonas, Helicobacter and Acinetobacter. On the other hand, for CRC 
patients, there is a decrease in Proteobacteria abundance in some studies, while other studies 
show that Campylobacter and Escherichia coli were significantly more abundant in CRC cases. 
(Table 2) Lactococcus was also found to be over-represented in the mucosa of adenoma and 
CRC patients. (Table 1 and 2) 
Individual studies discovered some over-represented bacteria listed in Table 1 and 2, for example 
Parvimonas micra, Akkermansia muciniphila, Leptotrichia, Methanobacteriales, but this results 
were not replicated in more than one study. However, it seems relevant to refer that Parvimonas 
micra showed strong association with CRC across ﬁve different cohorts, four of them ethnically 
different. (32) 
Studies also demonstrate a significant reduction in some bacteria. Bifidobacterium and 
Faecalibacterium were consistently under-represented in gut lumen and mucosa, both in 
adenoma and CRC patients. Lachnospiracae also showed reduction in adenoma and CRC 
patients, and there are also reports of Ruminococcus reduction, but only in CRC patients. (Table 
1 and 2) 
One study observed significant over-representation of the phylum Firmicutes in adenomas, one 
of the most abundant phyla in healthy human gut microbiota, as referred before. Another study 
reported under-representation of Firmicutes in CRC patients. (Table 1 and 2) It’s possible that 
organisms belonging to the same phylum have different functions in the gut microenvironment 
and therefore different abundance. 
The Bacteroides genus was found to be increased in adenoma cases in more than one study, 
and the majority of studies reported an over-representation of Bacteroides in CRC patients. 
However, one study discovered an under-representation of this genus in stools of CRC cases. 
Bacteroides possibly has both beneﬁcial and detrimental effects on host, through their colitogenic 
or probiotic potential. (33) 
There were also many discording results regarding some bacteria, such as Prevotella, Blautia 
and Roseburia, with studies reporting under or over-representation of this genus.  
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These differences and results that don’t replicate between studies seem to reveal that there is a 
diversified pattern in human CRC microbiome community. This makes sense since there is a 
natural inter-individual variation in normal gut microbiome, and regional differences must be taken 
into account. The different stage of tumor progression in different CRC individuals may also 
account for some part of this variance. Differences in sampling methods (stool sampling or 
mucosal biopsies), in the experimental approaches and the small sample size of some studies 
also contribute to these different results. The main goal is to identify within the normal variations, 
some patterns or specific signature associated with disease states.  
The fact that in many studies, the microbiota of individuals with polyps was found to be 
signiﬁcantly different to that of controls suggests a possible role of microbiota in the early stages 
of tumorigenesis, and that the microbiota differences in patients with cancer are not secondary to 
the cancer itself. However, this finding is not completely consistent between studies, since Zeller 
et al for example, concluded in a metagenomic study that adenomas microbiota composition was 
almost indistinguishable from healthy controls. (34) 
 
Bacteria clusters approach 
Some studies tried to address the complexity of the relationship between microbiota and disease 
by grouping the bacteria in co-abundance groups, based on the idea that the whole community 
structure can be more informative than individual taxa. (35) Flemer B. et al. results showed that 
individuals with CRC can be stratiﬁed into four different groups based on the abundance of 
bacterial co-occurrence networks. While the individual taxa signiﬁcantly more abundant in CRC 
cases were overabundant in only a subset of CRC cases, with the microbial clusters of CRC-
associated microbiota, at least one cluster was elevated more than twofold in all but one of the 
individuals with CRC. Nakatsu et al observed that a metacommunity characterized by microbes 
of oral origin (Fusobacterium, B. fragilis, Gemella, Peptostreptococcus and Parvimonas) forming 
a symbiotic network was associated with CRC.  (36) 
 
Prospective insight with murine models  
Zackular et al. used modified murine models (azoxymethane administrated as a mutagen for 
tumorigenesis induction and dextran sodium sulfate to induce inﬂammation) and treated them 
with antibiotics, to see in what way modifications in the microbiota induced by the antibiotics 
altered the number of tumors. They first realized that the relative abundance of Lactobacillus in 
the beginning of the experiment was inversely proportional to tumor burden in the end. They also 
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demonstrated that based on the microbiota composition at the beginning of the model they could 
predict the final number of tumors. So, targeting the gut microbiota in the beginning of dysbiosis 
is a possible way of improving tumorigenesis. In the authors opinion, microbiota’s role in CRC is 
possibly of polymicrobial nature. (37) Another study inoculated germ-free mice with fecal 
microbiota from different human subjects, some of them healthy and some with CRC. Then they 
also induced tumorigenesis using azoxymethane and concluded that the baseline microbiome 
structure was strongly associated with the final number of tumors, but the cancer status of the 
human donors was not. Generally, some gram-negative taxa (such as Bacteroides, 
Parabacteroides, Akkermansia) were strongly positively correlated with increased tumor, while 
members of the gram-positive Clostridiales were negatively correlated with tumors. (38)  
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Microbiome role in tumorigenesis promotion  
 
Bacterial Driver-Passenger Model and Alpha-bug Hypothesis 
One of the main questions investigators have asked is how do bacteria play a role in oncogenesis. 
Is it driven by multiple species acting collectively? Are there protagonists, or even single microbes 
capable of promoting cancer by themselves?  
Some authors started to come up with theories in an attempt to better understand the role of the 
bacteria in tumorigenesis.  
Harnold et al proposed a bacterial counterpart of the genetic “adenoma-carcinoma sequence” 
model formulated by Fearon and Vogelstein, the driver–passenger model. According to this 
model, the colonic mucosa of individuals more prone to develop CRC is colonized with certain 
pathogenic intestinal bacteria. These bacteria drive epithelial DNA damage by persistent 
inflammation, increasing cell proliferation and/or production of genotoxic substances. This would 
trigger the subset of pre-malignant lesions and the subsequent accumulation of mutations, 
leading to the initiation of carcinogenesis. There are designed “bacterial drivers”. (39) 
Then tumorigenesis, with rupturing and bleeding of the cancerous tissue, induces local intestinal 
alterations like changes in colonic barrier permeability and cellular metabolism. This changes 
would favor the proliferation of not only opportunistic bacteria, but maybe also commensal or 
probiotic bacteria, being this bacteria designated the “bacterial passengers”. They hipothyse that 
bacterial drivers may disappear from cancerous tissue as they are outcompeted by passenger 
bacteria with a growth advantage in the new tumoral microenvironment. (39) So, according to this 
theory, bacterial drivers and passengers have distinct temporal associations and probably distinct 
roles in tumorigenesis. (39) 
Another model, the “alpha­bug” hypothesis, proposed by Sears and Pardoll, relates to this one in 
the sense that the authors suggest that some microorganisms, designed “alpha-bugs” are directly 
pro-oncogenic, by their ability to modify the mucosal immune response and alter the colonic 
bacterial community. (22) By this mechanisms, the alpha bugs together with helper bacteria, 
possibly “crowd out” some beneficial species. This “alpha bugs” and the helper bacteria 
correspond to the driver bacteria, in the driver-passenger model. (39) However, according to this 
hypothesis, drivers persistently colonize the developing tumor and are not outcompeted by other 
bacteria. (22) This theory arose from their studies of enteroxigenic Bacteroides fragilis, and this 
microorganism is the protagonist of this model. (22) 
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The authors of the driver-passenger model propose as possible main bacterial-drivers pathogenic 
members of Bacteroides, such as enteroxigenic Bacteroides fragilis or the family 
Enterobacteriaceae, highlighting the uncertainty of this hypothesis. For main bacterial passengers 
are proposed the pathogens Fusobacterium or Streptococcus spp. and commensals like 
members of the Coriobacteriaceae family. (39)  
After this proposals many studies have emerged. Different studies found an enrichment of 
Fusobacterium in CRC but there’s also a study reporting over-representation in adenomas, noting 
that there was higher abundance in tumor that in adenoma samples. (31) This suggests a possible 
active involvement also in early CRC development. According to the alpha-bug theory, 
Fusobacterium could possibly be considered an alpha-bug. This information isn’t also 
incompatible with the driver-passenger theory since, as the authors highlight, this model does not 
exclude the involvement of some of the bacterial passengers in the beginning of pathogenic 
alterations. If the new tumoral microenvironmental provides preferable conditions for this bacteria, 
then they will continue to grow and participate in CRC progression. (39) Therefore, the bacterial 
driver-passenger model is apparently more complete, including the alpha-bug definition, but also 
proposing new hypothesis.   
In Tables 1 and 2 we can see that many of the bacteria reported as over and underrepresented 
in adenomas were not reported in CRC, and vice versa. For example, Porphyromonas, and 
Peptostreptococcus were not mentioned in any of the studies with adenomas, but were reported 
as over-represented in some of the studies with CRC samples. According to the driver-passenger 
theory, these bacteria could be possible bacteria-passengers. Mira-Pascual et al hypothysed that 
the family Enterococcaceae could be a possible driver, since besides being present in all samples, 
its proportion was higher in the adenoma group, comparing to healthy controls and 
adenocarcinoma. (31) Chen et al reported increased abundance of the family Coriobacteriaceae 
in CRC patients; besides, none of the adenoma studies analyzed reported significant alterations 
in Coriobacteriaceae abundance (Table 1 and 2). These findings support Harnold et al proposal 
that the family Coriobacteriaceae could be a possible passenger. Lactobacillus is enriched in 
adenomas and reduced in CRC samples, fitting in the bacteria-driver profile. Enterobacteriaceae 
is only reported to be enriched in adenoma samples, which corroborates the authors hypothesis 
on this family being possible bacteria-drivers (Table 1 and 2).  
Geng et al proposed that in Han Chinese population, Roseburia, which is overrepresented at 
tumor sites, could be a passenger bacteria, whereas Microbacterium and Anoxybacillus, 
overrepresented only in adjacent non-malignant tissue, could be possible drivers. (30) 
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The fact that there are some bacteria (Lachnospiracae family, Faecalibacterium, Bifidobacterium) 
down-regulated already in the adenoma phase and consistently diminished in CRC samples 
compared to normal controls (Table 1 and 2), is not contemplated or explained in this model.  
Concerning the Proteobacteria phylum, some bacteria like Escherichia coli and Campylobacter 
were only reported to be overexpressed in CRC samples (Table 1 and 2) and could be possible 
passengers, while Pseudomonas could be proposed as a possible driver since some studies 
found and enrichment in adenomas and there aren’t similar reports in CRC patients (Table 1 and 
2).  
Lu et al. when comparing adenomatous and adjacent non-adenoma tissues found similar 
microbiota structure. This might mean that the driver-passenger hypothesis may not be so 
relevant to the precancerous colon lesions. (25)  
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Mechanisms of interaction with the host 
 
The studies that have been presented so far have focused on identifying the taxonomic classes 
associated with CRC. Furthermore, it’s important to understand if and what bacterial products 
may have an impact in health and disease, and explore the potential bacterial interactions.  
Zackular et al results suggest that CRC is a polymicrobial disease, under the influence of many 
microorganisms and interconnected mechanisms. When they analyzed each patient individually, 
they rarely identified significant enrichment of every bacterial population studied. However, using 
the relative abundance data for a selected microbial panel, they managed to accurately classify 
the subjects as healthy, adenoma or carcinoma cases. (40) This suggests that along with some 
individual protagonists, microbiota may also have a strong collective role involving complex and 
interconnected mechanisms.   
Chen et al postulate that bacteria and it’s components function by directly interacting with the host 
or in an indirect way, through co-metabolism or metabolic exchange with the host. (28) According 
to their results, the predominant phylotypes in lumen of CRC patients (Erysipelotrichaceae, 
Prevotellaceae, and Coriobacteriaceae) have all been associated with metabolic disorders or 
energy metabolism and linked with obesity and high-fat diets. They also compared fecal and 
mucosal samples and found higher Firmicutes in gut lumen and higher Proteobacteria in mucosa. 
Firmicutes has been demonstrated to enhance energy harvest from diet and Proteobacteria 
potentially exhibits direct interaction with intestinal cells. (28) 
Zeller et al. found a global metabolic shift between CRC cases and controls, from utilization mainly 
of dietary fiber in the healthy participants, to predominant host-derived energy sources in CRC. 
Host cell-derived metabolites like amino acids were more abundant in the tumor environment, 
and data suggested an increased capacity of amino acids uptake and metabolism by the 
microbiota, via the putrefaction pathway. The metabolites from this pathway include polyamins, 
which if accumulated intracellularly can promote tumorigenesis. This finding raises the question 
of whether this increased putrefaction is a tumoral consequence or has a causal role in 
tumorigenesis. They also observed an enrichment in LPS metabolism, which has pro-
inflammatory potential, triggering an inflammatory signaling cascade. (34) 
Sinha et al found significant microbiome-metabolite correlations in human feces, and also 
microbiome-metabolite differences between CRC cases and controls. Fecal samples from CRC 
patients were associated with significantly under-representation of Clostridia, Lachnospiraceae, 
p-aminobenzoate and conjugated linoleate, and with higher levels of Fusobacterium, 
Porphyromonas, palmitoyl-sphingomyelin and p-hydroxy-benzaldehyde. Palmitoyl-
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sphingomyelin correlated directly with abundances of Enterobacteriaceae, Actinobacteria and 
Firmicutes. However, it isn’t known yet how this metabolites impact CRC risk. (41)  
Nugent et al also found that the metabolome differed significantly between adenoma patients and 
healthy individuals. It is noteworthy an increase of the inflammatory metabolite Prostaglandin E2 
and a decrease in two antioxidant-related metabolites, 5-oxoproline and diketogulonic acid. This 
suggests the importance of inflammation and possible role of oxidative stress in adenoma 
development. (42) 
Ohigashi et al detected lower concentrations of short chain fatty acids in feces of CRC individuals, 
and an associated increase in pH. More precisely, three types of organic acids (acetic acid, 
propionic acid and butyric acid), usually the most abundant in the gut, were reduced. (43) Short 
chain fatty acids are important final products of bacterial carbohydrate fermentation in the gut. 
Butyrate in particular is thought to be important in maintenance of a healthy intestinal 
environment. It’s considered to be the preferred energy substrate for the colonocytes, and 
apparently stimulates a physiologic pattern of cell proliferation and suppresses tumor cells 
proliferation in the colonic crypts. (44, 45) It also participates in the maintenance of intestinal 
acidity, prevention of toxin absorption and promotion of cancer apoptosis. (43) According to Hold 
et al, some of the main butyrate-producing bacteria are Roseburia intestinalis, Faecalibacterium 
prausnitzii and Eubacterium hallii. (46) In Tables 1 and 2 we can see that Faecalibacterium and 
Roseburia were found diminished in CRC/adenoma cases in some studies. In adenoma cases, 
fecal short chain fatty acids and pH were intermediate between normal individuals and CRC 
cases, and there were no differences detected between different CRC stages. This suggests that 
these variations are not consequent to the cancer itself. (43) Baxter et al. found a negative 
correlation between the number of tumors and butyrate production capacity. (38) 
It was also found a positive correlation between tumor count and mucin degradation. Disruption 
of the mucosal barrier integrity by mucin degradation could possibly lead to increased 
inflammation. (38) 
This are some of the main mechanisms that are thought to take part in promotion of 
carcinogenesis by bacterial populations. However, there’s a much wider range of possible 
interactions and mechanisms studied, and mainly a lot of questions to answer.  
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Role of individual intestinal bacteria 
 
Besides the belief that the microbiota influence in carcinogenesis is collective and polymicrobial, 
studies have identified some species consistently increased in the tumor microenvironment and 
there is growing evidence of a protagonist role of this species in tumorigenesis. 
 
Fusobacterium nucleatum 
Fusobacterium species are gram-negative, anaerobic bacteria from bacteroidaceae family. (47) 
As we can see from Tables 1 and 2, there is accumulating evidence linking Fusobacterium with 
colorectal cancer. Fusobacterium nucleatum is the most common microorganism in the 
subgingival biofilm. It is considered a relevant pro-inflammatory factor in the oral cavity and is 
involved in periodontal diseases. (48) It has been consistently found in adenoma and tumoral 
tissues, leading to the thought that maybe it also participates in gastrointestinal diseases, in 
particular colorectal tumorigenesis.  
McCoy et al, besides finding increased abundance of Fusobacterium in adenoma mucosa 
samples, found a positive correlation between local cytokine gene expression and Fusobacterium 
abundance, in particular for TNF-α and IL-10.(49) This leads us to speculate that possibly 
Fusobacterium conditions mucosal inflammation and therefore contributes to the initial 
tumorigenesis. Kostic et al. conducted an experiment using min1 mice and found that 
Fusobacterium accelerated the onset of colonic tumors and recruited tumor-infiltrating myeloid 
cells, with immune suppressive activity. Tumors from the min mice exposed to Fusobacterium 
had a pro-inflammatory expression signature, characterized by an increase in tumor-associated 
neutrophils, tumor-associated macrophages and dendritic cells including CD103+regulatory 
dendritic cells. This subtype of dendritic cells expressing CD103 integrin can promote the 
expansion of Foxp3+regulatory T cells, a CD4+ T cell subset that inhibits cytotoxic and effector T 
cells, therefore diminishing anti-tumor immunity. This pro-inflammatory environment could help 
tumor progression. (50) Another possible competitive advantage could be due to the fact that 
Fusobacterium nucleatum doesn’t have the need to compete for glucose, a substrate used by the 
                                                             
1 Multiple intestinal neoplasia (Min) mouse strain is considered the classic murine model of colon tumorigenesis and is 
heterozygous for the adenomatosis polyposis coli (APC) allele. Mutations in APC occur in nearly all human colon 
cancers and are the characteristic molecular defect in Familial Adenomatosis Polyposis syndrome. (22) 
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tumoral cells. Besides that, F. nucleatum has a rudimentary electron transport chain, which allows 
it to survive in the hypoxic tumoral microenvironment. (50) 
Mima et al tried to test the hypothesis that the amount of F. nucleatum in colorectal carcinoma 
tissue is inversely correlated with the density of T cells in tumor tissue, knowing that higher levels 
of T cell infiltrates in colorectal carcinoma have been associated with better outcomes. They found 
an inverse association between the amount of F. nucleatum and CD3+ T cells density. (51)  
Tahara et al results showed that a higher level of Fusobacterium was related with a molecularly 
distinct type of cancer, characterized by high rates of CpG island methylation microsatellite 
instability. With this results they suggest that the higher Fusobacterium levels in CRC are not just 
an epiphenomenon of the cancer itself. The fact that Fusobacterium levels were also high in the 
adjacent normal tissues corroborates this idea. (52) A recent study also demonstrated that the 
abundance of Fusobacteria was similar between tubular adenomas and sessil serrated 
adenomas, suggesting that Fusobacteria could possibly influence both tumorigenesis pathways. 
(53) It was observed a higher presence of F. nucleatum in tumors than in polyps in both fecal and 
mucosal samples.  It’s tempting to speculate that a higher presence of Fusobacterium would be 
representative of high risk of CRC, and could also represent a potential biomarker of 
carcinogenesis development. (31) A recent study showed that the amount of F. nucleatum DNA 
in colorectal cancer tissue is positively associated with shorter survival. This findings open doors 
for investigations exploring F.nucleatum as a potential prognostic biomarker. (54) 
 
Fusobacterium nucleatum 
↑ cytokine  gene 
expression 
Creates pro-inflammatory environment 
• ↑ tumor-associated neutrophils 
• ↑ tumor-associated macrophages 
• ↑ dendritic cells (CD103+ 
regulatory) 
↑ Foxp3+regulatory T 
cells 
↓ anti-tumor  immunity 
no need for glucose survives in hypoxic environment 
↓ CD3+ T cells density 
Figure 1. Fusobacterium nucleatum - Mechanisms of tumorigenesis 
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Escherichia coli 
E.coli is a commensal microorganism of the human intestinal microbiota. However, some 
pathogenic strains developed the ability to induce chronic inﬂammation and/or produce toxins. 
(55) Four phylogroups are known: A, B1, B2 and D. Commensal strains usually belong to the A 
or B1 phylogenetic group and pathogenic strains normally belong to B2 or D phylogroup. 
Pathogenic groups have the ability to produce more virulent factors than commensal strains.  The 
genotype B2 harbors the pks genomic islands. This islands lead to the production of a genotoxin, 
colibactin. (56) Infection by pks positive E. coli strains leads to production of oxygen species, pro-
inflammatory cytokines and protease secretion. These can trigger DNA-double strand breaks. 
(57) 
These bacteria are part of the Enterobacteriaceae family, and bacteria from this family produce 
proteins called bacteriocins. Kohoutuva et al found a significant higher production of bacteriocins 
in patients with advanced adenoma when compared to patients with non-advanced adenoma, 
and also higher production of bacteriocins with more advanced CRC stages. They also found 
significantly higher abundance of E.Coli phylogroup D in CRC patients and associated the B2 
phylogroup with right-sided CRC. (57) 
Arthur et al developed an experiment relating inflammation with cancer. First, they concluded that 
colitis-susceptible IL10− / − mouse strain developed a different microbiota comparing to wild-type 
controls, suggesting that inflammation alters the microbiota. The luminal microbiota of colitis-
susceptible mice exhibited a 100-fold increase in E. coli. Through the addition of a colon-specific 
carcinogen (azoxymethane) they were able to conclude that this microbial shift was related to 
inflammation and not with cancer itself. In a second phase, they decided to create two groups of 
colitis-susceptible mouse with azoxymethane, and one group was mono-associated with E. coli 
whereas the other group was colonized with Enterococcus faecalis. 80% of E. coli mono-
associated mice developed adenocarcinomas, while E. faecalis mono-associated mice rarely 
developed tumors. They also investigated the presence of pks + E. coli in IBD, CRC patients and 
controls, and found a significantly higher percentage in inflammatory bowel disease and CRC 
patients, suggesting a possible association. These investigators went deeper in the investigation 
and analyzed the infection of a rat intestinal epithelial cell line with a pks deficient E. coli strain, 
and compared with infection of the same cell line with a normal pks + E. coli strain. Infection with 
normal E.Coli induced DNA damage in 30% of cells, whereas infection with pks deficient E.Coli 
induced DNA damage in less than 5%. Moreover, when infecting germ-free and colitis-susceptible 
mice (with and without azoxymethane treatment) with pks deficient E. coli strain and normal pks 
+ E. coli strain, they found decreased tumor multiplicity and invasion mice with pks deficient E. 
coli strain, without alterations in intestinal inflammation. (58) 
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Bonnet et al. found a significant relationship between poor prognostic factors for colon cancer and 
colonization of the mucosa by E. coli. Also, it was observed that pathogenic cyclomodulin-positive 
E. coli strains were more prevalent on the mucosa of patients with more advanced colon cancer 
stages. They also inoculated min and  wild-type mice with a colon cancer–associated E. coli strain 
and verified a significant increase in the size and number of tumors compared to controls only in 
min mice. This results can also suggest that tumor development induced by infection with E.coli 
requires a ﬁrst hit, such as an APC mutation. (55) 
 
  
E.coli B2
pks genomic 
islands
production of 
colibactin
oxygen species
pro-
inflammatory 
cytokines
protease 
secretion
DNA-double 
strand breaks
Figure 2. E. Coli - possible mechanism of patogeny 
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Enteroxigenic Bacteroides fragilis 
Bacteroides fragilis is a common colonizer of the human colon, but represents a minority of the 
bacterial community. Enteroxigenic B.fragilis is a molecular class of B. fragilis characterized by 
the secretion of a metalloprotease toxin termed the B. fragilis toxin. This bacteria appears to 
behave either as a pathogen or a commensal. It is associated with diarrheal illnesses, but 
asymptomatic colonization is also common. (22) 
Studies investigating the mechanism of action of BFT showed that the toxin stimulates cleavage 
of E-cadherin, a structural protein comprising the zonula adherens of CECs and that acts as a 
suppressor of colon tumorigenesis. Cleavage of E-cadherin by BFT leads to increased colonic 
permeability and exposition of the submucosa to luminal bacterial antigens, possibly inducting 
colon inflammation. (22) This cleavage also leads to activation of β-catenin nuclear signaling, with 
consequent activation of Wnt signaling, leading to cell proliferation. In addition, BFT also 
stimulates synthesis and secretion of pro-inﬂammatory cytokines (IL-8 and TNF-a) through 
activation of nuclear factor-ƙB signaling. (22) A study analyzed the T cell-dependent mucosal 
immune responses in ETBF-colonized mice and compared it with controls. ETBF rapidly induced 
activation of Stat3, a transcription factor that mediates, in part, T cell lineage development and is 
also regulator of oncogenesis. Stat3 activation is required for the induction of Th17 immune 
responses, whose effector cytokine is IL-17. Two populations of T cells, were identiﬁed to be 
producing IL-17 in the colon mucosa of ETBF-colonized mice but not in controls. They also further 
blocked IL-17and observed that it signiﬁcantly inhibited ETBF-induced colon tumorigenesis. (22) 
So ETBF is thought to alter CEC and mucosal immune function to promote oncogenic mucosal 
events. It may also promote DNA damage either through direct action of the toxin on CEC or 
reactive oxygen species released by inflammatory cells. (22) 
Enteroxigenic 
Bacteroides fragilis
cleavage of E-
cadherin
↑ colonic permeability 
↑ submucosa 
exposition to antigens
↑ inflammation
β-catenin signaling 
activation
Wnt signaling 
activation
cell proliferation
nuclear factor-ƙB 
signaling activation
secretion of pro-
inﬂammatory citocines 
(IL-8 and TNF-a)
Stat3 activation T cells Th17 induction ↑ IL-17
DNA damage
(direct and ROS) 
Figure 3.  Enteroxigenic Bacteroides fragilis – mechanisms of tumorigenesis 
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Biofilms 
 
Biofilms consist in aggregations of microbial communities encased in a matrix, that adhere and 
invade the colonic mucus layer and therefore, directly contact with mucosal epithelial cells. (59) 
They are found in numerous chronic mucosal diseases. It’s been a recent area of research 
whether these microbial formations play a role in CRC initiation. Dejea et al showed that right 
sided CRC is biofilm-positive in 87%, and 100% of adenomas were also biofilm positive. On the 
contrary, tumors located in the transverse and descending colon displayed biofilms in 13% and 
0% of CRCs and adenomas, respectively. This points out the possibility of biofilms being a distinct 
characteristic of proximal tumors. (59) All biofilm-covered CRCs showed bacterial invasion into 
the tumor, opposite to the biofilm-negative tumors. The predominant bacteria featuring the 
biofilms were Bacteroidetes and Firmicutes, and less commonly Fusobacteria and Gamma-
proteobacteria. Biofilms were also present in normal colon tissue from the tumor patients. Dejea 
et al also showed it was associated with reduced or altered E-cadherin, enhanced IL-6 and with 
Stat3 activation. This suggests that biofilms might increase epithelial permeability and promote 
procarcinogenic tissue inflammation. (59) 
Johnson et al tried to better understand the metabolic influence of biofilms on colon tissues. They 
found an enrichment of a polyamine (N1, N12-diacetylspermine) in both biofilm positive cancer and 
normal tissues, comparing with biofilm-negative tumor tissues and healthy controls. The authors 
propose a model where bacterial polyamine metabolites act synergistically to promote biofilm 
formation and enhance cellular proliferation, possibly leading to oncogenic transformation in 
colonic epithelial cells. (60) 
The investigation concerning biofilms and their potentially pro-oncogenic role is still beginning to 
grow and there aren’t yet many answers concerning this topic.   
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Beneficial roles of bacteria 
 
Many authors hypothesized that certain bacteria may have a role in protection against pathogens 
and possibly prevent the progression of cancer. (28) 
Feng et al observed that some of the control-enriched species were lactic acid-producing bacteria 
Biﬁdobacterium animalis, Streptococcus mutans and S. thermophilus. Lactic acid participates in 
gut acidification and inhibits intestinal amino acid degradation. It was also reported to accelerate 
colon epithelial cell turnover in mice. There is evidence that advanced colorectal adenoma or 
carcinoma patients are deﬁcient in lactic acid-producing commensals such as Biﬁdobacterium, 
that could potentiate daily epithelial renewal and inhibit potential pathogens. (61) Lactococcus, 
also a lactic acid-producing bacteria, were over-represented in CRC patients besides playing a 
probiotic role in colon. The question that remains is whether these solely beneﬁt from the CRC 
microenvironment or if they also play an active part in disease. (62) 
Short chain fatty acids are important microbial metabolites and butyrate has been shown to have 
substantial anti-tumorigenic properties. (44) As approached before in this review, butyrate is 
thought to be important in the maintenance of a healthy intestinal environment, participating in 
several benefic and antitumoral processes. Some of the main butyrate-producing bacteria 
(Roseburia intestinalis, Faecalibacterium prausnitzii) were found diminished in CRC/adenoma 
cases in some studies.  This loss of short chain fatty acids producing bacteria populations is likely 
to play a synergistic role in potentiating tumorigenesis. (40) 
Lactobacillus spp. interacts with the host by binding to human mucus and they are currently used 
as probiotics. It is not yet understood if the effect is direct (through immune modulation, for 
example) or indirect (via alteration of the intestinal microbiota) (48) 
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Clinical Relevance  
 
Zackular et al. identified a panel of bacterial populations that could indicate both the progression 
from healthy tissue to adenoma and the progression from adenoma to carcinoma, and created a 
screening model combining BMI, FOBT, and the microbiome data. This model provided excellent 
discriminatory ability. They also compared the microbiome test with the FOBT, and assessed that 
the likelihood ratio of a positive FOBT was lower than the likelihood ratio of a positive microbiome 
test. For better understanding, they explained that for a 65 years old person with a positive FOBT, 
there was a 1 in 15 chance of having an adenoma. This contrasts with 1 in 9 chance using a 
positive microbiome test in the same 65-year old. It was concluded that the sensitivity of the 
microbiome test was greater than the sensitivity of the FOBT. (40)  
George Zeller et al used metagenomics to explore microbiota potential for CRC detection, 
hypothesizing that a combination of marker species could be used to improve screening. They 
selected the four most discriminative species, (two Fusobacterium species, Porphyromonas 
asaccharolytica and Peptostreptococcus stomatis) enriched in CRC patients. This metagenomic 
classifier proved to be slightly better than FOBT. They also combined the two tests and obtained 
a sensitivity 45% higher than FOBT alone. The authors then assessed for external validation, 
applying the classifier in cohorts from different countries. They concluded that high accuracy 
detection was still possible even with cohort differences. It was also concluded this classifier has 
potential for early detection, since the sensitivity was similar for early-stage and late-stage CRC. 
These markers were also tested in IBD patients, and the most discriminative markers were all 
significantly higher in CRC, proving its specificity for CRC. (34) The future application of this 
markers in population screening relies on the development of cost-effective methods. With this in 
mind, Zeller et al tested an alternative 16S sequencing classifier for CRC, and it accomplished 
almost as good an accuracy as the metagenomic model. (34) 
A recent study tested the effect of probiotic Lactobacillus salivarius REN2 in a 1,2-dimethyl 
hydrazine (DMH - induces colon carcinogenesis) induced mice model. Injection with DMH 
significantly altered the gut microbiota, while Lactobacillus salivarius REN promoted some 
reversion of this alterations. With carcinogenesis induction, the amount of Ruminococcus and 
Clostridiales increased, while Prevotella sp decreased. The probiotic bacteria reduced the amount 
of Ruminococcus, Clostridiales and Bacteroides dorei, and increased the amount of Prevotella. 
                                                             
2 L. salivarius REN is a novel strain isolated from the fecal samples of Chinese centenarians (63) 
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These results suggest that some bacteria are capable of modulating other bacteria populations, 
and could possibly be used as a way to prevent carcinogenesis. (64) 
Baxter et al found a positive correlation between tumor count and mucin degradation, which would 
be interesting to confirm with further experiments since blockage of mucin degradation could be 
used as a future therapeutic target in tumorigenesis prevention or delay. (38) 
A recent study concluded that probiotics Clostridium butyricum and Bacillus subtilis inhibited the 
growth of CRC cells in mice both in vitro and in vivo, by promoting apoptosis and triggering cell 
cycle arrest. The anticancer effects seem to relate with the production of antiproliferative 
compounds (butyrate, bacitracin), suppression of inflammation and immune modulation. (65) The 
next step is to investigate if these findings replicate in human studies.  
Researchers are also exploring the possibility that the negative effects of Fusobacterium might 
be regulated by therapeutic interventions. Recently, Kumar et al. identified a set of target proteins 
suggested to be crucial for survival and pathogenicity of the bacteria. This finding can lead to 
future development of drugs to target these proteins and therefore diminish Fusobacterium effect 
on cancer progression. (66) A recent Chinese study demonstrated that Berberine, a component 
of the Chinese herb Coptis chinensis, reversed the F. nucleatum-mediated increase in 
opportunistic pathogens and also inhibited some tumorigenesis-related pathways. (67) 
It’s also plausible to speculate that short chain fatty acids producing bacteria, as other beneficial 
bacteria, could integrate possible health biomarkers in CRC prevention.  
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Conclusion and future directions 
 
Overall, the relation between microbiome and colorectal cancer is a growing area of research, 
complex, broad and continually developing. There is much that we already know, but there are 
many more questions to answer. 
There is sustained evidence that microbiome is indeed related to colorectal cancer, and there has 
been a lot of research exploring and comparing the composition of clinically different populations. 
However, it’s not fully understood if there is a causal relation, if the changes are a cause or 
consequence of cancer itself, or a bit of both. Further research is needed to better understand the 
vast and complex mechanisms and interactions involved. Another challenge is to find a 
microbiome signature associated with colorectal cancer, given the great interindividual variety of 
microbiome populations. The most consistently associated microorganism so far, and therefore 
the one showing most applicability potential is Fusobacterium nucleatum. It’s also important to 
highlight and further explore the fact that besides the potential pathogenic role, some bacterial 
species may also play a protective role in colorectal cancer. 
This area of research has a promising potential in improving prevention, diagnosis and even 
treatment of colorectal cancer. Modulation of the microbial flora could possibly be used in cancer 
prevention. The actual screening and diagnostic methods are far from ideal: FOBT lacks 
sensitivity and specificity and colonoscopy is invasive and expensive. Microbiota can possibly be 
used to create screening biomarkers and therefore improve screening and diagnosis. It may also 
contribute to more directed and personalized treatments. The possibilities are immeasurable, but 
further prospective human studies in large populations are needed to answer the unknown 
questions and provide better knowledge about this complex but ultimately fascinating area. 
 
  
Beyond Microbiota and Colorectal Cancer: A Critical Review 
30 
 
Acknowledgements 
 
Gostaria de agradecer em primeiro lugar ao meu orientador, Prof. Dr. Gil Faria, pela constante 
disponibilidade e ajuda. Não posso deixar de ressalvar o excelente professor que é, e agradecer 
por me ter cativado para a cirurgia e por tudo o que me ensinou.  
Agradeço também à minha família pelo apoio incondicional, por me fazerem acreditar que tudo 
é possível e por me lembrarem sempre do que realmente importa.  
Agradeço ao meu namorado, melhor amigo e companheiro de todas as horas, por nunca me 
deixar duvidar do meu valor, por me amparar as quedas e multiplicar os momentos felizes.  
Aos meus amigos do coração, gostava de agradecer por estes anos incríveis, por estarem 
sempre lá para mim nos piores momentos e por todos os bons momentos e conquistas que 
celebramos juntos. 
 
  
Beyond Microbiota and Colorectal Cancer: A Critical Review 
31 
 
Appendices 
Table 1 
  
Phylum Microbiota 
Change in 
adenomas compared 
to control 
Type 
of 
sample 
Reference 
Firmicutes  reduced mucosa (25) 
 
Enterococcaceae increased 
feces 
and 
mucosa 
(31) 
Lactobacillus increased mucosa (26) 
Lactococcus increased mucosa (25) 
Ruminococcaceae increased feces (40) 
Faecalibacterium reduced 
Mucosa 
and 
feces 
(31) 
Solibacillus reduced mucosa (25) 
Bacteroidetes     
 
Prevotella increased 
Mucosa 
and 
feces 
(31) 
Porphyromonadaceae increased feces (40) 
Bacteroides 
Increased (mucosa and 
feces) 
Mucosa 
and 
feces 
(31)  
B. dorei increased feces (61) 
B. massiliensis increased feces (61) 
Cloacibacterium increased mucosa (26) 
Lachnospiracae reduced feces (40) 
Actinobacteria     
 
Bifidobacterium reduced 
Feces 
and 
mucosa 
(31) 
Fusobacteria     
 
Fusobacterium increased 
Mucosa 
and 
feces 
(31, 49) 
Proteobacteria 
 increased 
Mucosa, 
feces 
(25, 68) 
 Enterobacteriaceae increased feces (40) 
Helicobacter increased mucosa (26) 
Acinetobacter increased mucosa (26) 
Pseudomonas increased 
Mucosa, 
feces 
(25, 26, 40) 
Acidovorax increased mucosa (26) 
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Table 2  
Phylum Microbiota 
Change in 
CRC 
compared to 
control  
Type of 
sample 
Reference 
Firmicutes  increased mucosa (62) 
 Lactobacillales  Increased mucosa (28) 
Erysipelotrichaceae Increased feces (28) 
Peptostreptococcus increased 
rectal 
swab, 
feces, 
mucosa 
(28, 32, 35) 
Mogibacterium increased 
rectal 
swab 
(28) 
Clostridium difficile increased feces (48) 
Enterococcaceae increased feces (40, 69) 
Acidaminobacter Increased feces (70) 
Phascolarctobacterium Increased feces (70) 
Parvimonas increased mucosa (35) 
Parvimonas micra increased feces (32) 
Solobacterium 
moorei 
increased feces (32) 
Lactococcus increased mucosa (62) 
Blautia 
reduced (rectal 
swab) /increased 
(mucosa and 
feces) 
rectal 
swab, 
mucosa 
and 
feces 
(28, 31) 
Ruminococcus 
reduced 
(mucosa, feces), 
increased 
(mucosa) 
mucosa, 
feces 
(35, 40, 70, 
71) 
Roseburia 
Reduced 
(feces)/increased 
(mucosa) 
feces, 
mucosa 
(30, 35, 69) 
Lactobacillus reduced feces (69) 
Dorea reduced feces (70) 
Faecalibacterium reduced 
mucosa, 
rectal 
swab, 
feces 
(28, 31, 69) 
Clostridia reduced feces (27, 41) 
Anoxybacillus reduced mucosa (30) 
Bacteroidetes Lachnospiracae reduced feces (41, 70) 
B. ovatus increased feces (61) 
B. vulgatus increased feces (61) 
Porphyromonas increased 
rectal 
swab, 
feces, 
mucosa 
(27, 28, 35, 
40, 41) 
Prevotella 
reduced (feces), 
increased 
(mucosa and 
feces) 
mucosa, 
feces 
(31, 70) 
Parabacteroides reduced mucosa (71) 
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Phylum Microbiota 
Change in 
CRC 
compared to 
control  
Type 
of 
sample 
Reference 
Fusobacteria     
 
Fusobacterium increased 
rectal 
swab, 
mucosa, 
feces  
(27, 28, 31, 
32, 35, 40, 
41, 48, 62, 
69, 71) 
Leptotrichia increased mucosa (71) 
Euryarchaeota     
 
Methanobacteriales increased 
feces 
and 
mucosa 
(31) 
Proteobacteria  reduced mucosa (62) 
 Citrobacter farmeri  Increased feces (70) 
Escherichia coli increased 
feces, 
mucosa 
(55, 61, 72) 
Campylobacter  increased 
mucosa, 
feces
  
(27, 33) 
Verrucomicrobia     
 Akkermansia muciniphila increased feces (70) 
Actinobacteria     
 Coriobacteriaceae increased feces (28) 
Microbacterium reduced mucosa (30) 
Bifidobacterium reduced 
rectal 
swab, 
feces, 
mucosa 
(28, 31, 61, 
72) 
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